KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Total Debt (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Total Debt data on record, last reported at $598.3 million in Q4 2025.

  • For Q4 2025, Total Debt changed 0.1% year-over-year to $598.3 million; the TTM value through Dec 2025 reached $598.3 million, changed 0.1%, while the annual FY2025 figure was $598.3 million, 0.1% changed from the prior year.
  • Total Debt reached $598.3 million in Q4 2025 per EW's latest filing, roughly flat from $598.2 million in the prior quarter.
  • Across five years, Total Debt topped out at $598.3 million in Q4 2025 and bottomed at $595.2 million in Q1 2021.
  • Average Total Debt over 5 years is $596.8 million, with a median of $596.8 million recorded in 2023.
  • Peak YoY movement for Total Debt: rose 0.12% in 2021, then rose 0.1% in 2025.
  • A 5-year view of Total Debt shows it stood at $595.7 million in 2021, then rose by 0.1% to $596.3 million in 2022, then increased by 0.12% to $597.0 million in 2023, then grew by 0.12% to $597.7 million in 2024, then increased by 0.1% to $598.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $598.3 million in Q4 2025, $598.2 million in Q3 2025, and $598.0 million in Q2 2025.